Skip to main content
Erschienen in: Medizinische Klinik - Intensivmedizin und Notfallmedizin 4/2018

04.05.2018 | Direkte orale Antikoagulanzien | Leitthema

Blutungen unter direkten oralen Antikoagulanzien

Auftreten und Therapie bei Intensivpatienten

verfasst von: Prof. Dr. H. M. Hoffmeister, H. Darius, M. Buerke

Erschienen in: Medizinische Klinik - Intensivmedizin und Notfallmedizin | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Verwendung von Antikoagulanzien ist mit einem erhöhten Blutungsrisiko verbunden und Blutungskomplikationen können lebensbedrohlich sein. Derzeit liegt der Fokus auf Blutungen unter direkten oralen Antikoagulanzien (DOAK), da Antidote oder spezifische Maßnahmen für einige der DOAK fehlen. Darüber hinaus können routinemäßige Gerinnungstests nicht verwendet werden, um den Grad der Antikoagulation unter DOAK zu bestimmen. Dadurch wird es schwieriger festzustellen, ob der gerinnungshemmende Effekt nicht mehr vorhanden ist. In diesem Artikel werden die Behandlung von Blutungen bei Patienten mit DOAK auf der Intensivstation, die Indikationen für die Substanzen sowie Einzelheiten ihrer Verabreichung und Überwachung dargestellt.
Literatur
1.
Zurück zum Zitat Barnes GD, Ageno W, Ansell J et al (2015) Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 13:1154CrossRefPubMed Barnes GD, Ageno W, Ansell J et al (2015) Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 13:1154CrossRefPubMed
2.
Zurück zum Zitat Chai-Adisaksopha C, Hillis C, Isayama T et al (2015) Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 13:2012CrossRefPubMed Chai-Adisaksopha C, Hillis C, Isayama T et al (2015) Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 13:2012CrossRefPubMed
3.
Zurück zum Zitat Inohara T, Xian Y, Liang L et al (2018) Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality. JAMA 319:463CrossRefPubMedPubMedCentral Inohara T, Xian Y, Liang L et al (2018) Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality. JAMA 319:463CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Koretz RL (2015) Neither dabigatran nor rivaroxaban were linked to increased GI bleeding compared with warfarin. Ann Intern Med 163:JC13CrossRefPubMed Koretz RL (2015) Neither dabigatran nor rivaroxaban were linked to increased GI bleeding compared with warfarin. Ann Intern Med 163:JC13CrossRefPubMed
5.
Zurück zum Zitat Southworth MR, Reichman ME, Unger EF (2013) Dabigatran and postmarketing reports of bleeding. N Engl J Med 368:1272CrossRefPubMed Southworth MR, Reichman ME, Unger EF (2013) Dabigatran and postmarketing reports of bleeding. N Engl J Med 368:1272CrossRefPubMed
6.
Zurück zum Zitat Sharma M, Cornelius VR, Patel JP et al (2015) Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 132:194CrossRefPubMedPubMedCentral Sharma M, Cornelius VR, Patel JP et al (2015) Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 132:194CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Chai-Adisaksopha C, Crowther M, Isayama T, Lim W (2014) The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124:2450CrossRefPubMed Chai-Adisaksopha C, Crowther M, Isayama T, Lim W (2014) The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124:2450CrossRefPubMed
8.
Zurück zum Zitat Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955CrossRefPubMed Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955CrossRefPubMed
9.
Zurück zum Zitat Hylek EM, Held C, Alexander JH et al (2014) Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 63:2141CrossRefPubMed Hylek EM, Held C, Alexander JH et al (2014) Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 63:2141CrossRefPubMed
10.
Zurück zum Zitat Piccini JP, Garg J, Patel MR et al (2014) Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 35:1873CrossRefPubMed Piccini JP, Garg J, Patel MR et al (2014) Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 35:1873CrossRefPubMed
11.
Zurück zum Zitat Patel MR, Hellkamp AS, Fox KA, ROCKET AF Executive Committee and Investigators (2016) Point-of-care warfarin monitoring in the ROCKET AF trial. N Engl J Med 374:785CrossRefPubMed Patel MR, Hellkamp AS, Fox KA, ROCKET AF Executive Committee and Investigators (2016) Point-of-care warfarin monitoring in the ROCKET AF trial. N Engl J Med 374:785CrossRefPubMed
12.
Zurück zum Zitat Lopes RD, Guimarães PO, Kolls BJ et al (2017) Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood 129:2980CrossRefPubMed Lopes RD, Guimarães PO, Kolls BJ et al (2017) Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood 129:2980CrossRefPubMed
13.
Zurück zum Zitat van der Hulle T, Kooiman J, den Exter PL et al (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12:320CrossRefPubMed van der Hulle T, Kooiman J, den Exter PL et al (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12:320CrossRefPubMed
14.
Zurück zum Zitat Fihn SD, Callahan CM, Martin DC et al (1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 124:970CrossRefPubMed Fihn SD, Callahan CM, Martin DC et al (1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 124:970CrossRefPubMed
15.
Zurück zum Zitat Sardar P, Chatterjee S, Chaudhari S, Lip GY (2014) New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 62:857CrossRefPubMed Sardar P, Chatterjee S, Chaudhari S, Lip GY (2014) New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 62:857CrossRefPubMed
16.
Zurück zum Zitat Scaglione F (2013) New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 52:69CrossRefPubMed Scaglione F (2013) New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 52:69CrossRefPubMed
17.
Zurück zum Zitat Samuelson BT, Cuker A, Siegal DM et al (2017) Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 151:127CrossRefPubMed Samuelson BT, Cuker A, Siegal DM et al (2017) Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 151:127CrossRefPubMed
18.
Zurück zum Zitat Eller T, Busse J, Dittrich M et al (2014) Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clin Chem Lab Med 52:835CrossRefPubMed Eller T, Busse J, Dittrich M et al (2014) Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clin Chem Lab Med 52:835CrossRefPubMed
19.
Zurück zum Zitat Herrmann R, Thom J, Wood A et al (2014) Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 111:989CrossRefPubMed Herrmann R, Thom J, Wood A et al (2014) Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 111:989CrossRefPubMed
20.
Zurück zum Zitat Neyens R, Bohm N, Cearley M et al (2014) Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG(®)) to guide decision-making. J Thromb Thrombolysis 37:80CrossRefPubMed Neyens R, Bohm N, Cearley M et al (2014) Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG(®)) to guide decision-making. J Thromb Thrombolysis 37:80CrossRefPubMed
21.
Zurück zum Zitat Xu Y, Wu W, Wang L et al (2013) Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis 24:332CrossRefPubMed Xu Y, Wu W, Wang L et al (2013) Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis 24:332CrossRefPubMed
22.
Zurück zum Zitat Casutt M, Konrad C, Schuepfer G (2012) Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM. Anaesthesist 61:948CrossRefPubMed Casutt M, Konrad C, Schuepfer G (2012) Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM. Anaesthesist 61:948CrossRefPubMed
23.
Zurück zum Zitat Siegal DM, Garcia DA, Crowther MA (2014) How I treat target-specific oral anticoagulant-associated bleeding. Blood 123:1152CrossRefPubMed Siegal DM, Garcia DA, Crowther MA (2014) How I treat target-specific oral anticoagulant-associated bleeding. Blood 123:1152CrossRefPubMed
24.
Zurück zum Zitat Tomaselli GF, Mahaffey KW, Cuker A et al (2017) ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol 70:3042CrossRefPubMed Tomaselli GF, Mahaffey KW, Cuker A et al (2017) ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol 70:3042CrossRefPubMed
25.
Zurück zum Zitat Kaatz S, Kouides PA, Garcia DA et al (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 87(Suppl 1):S141CrossRefPubMed Kaatz S, Kouides PA, Garcia DA et al (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 87(Suppl 1):S141CrossRefPubMed
26.
Zurück zum Zitat Marlu R, Hodaj E, Paris A et al (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108:217CrossRefPubMed Marlu R, Hodaj E, Paris A et al (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108:217CrossRefPubMed
27.
Zurück zum Zitat Wong H, Keeling D (2014) Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding. Br J Haematol 166:152CrossRefPubMed Wong H, Keeling D (2014) Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding. Br J Haematol 166:152CrossRefPubMed
28.
Zurück zum Zitat Htun KT, McFadyen J, Tran HA (2014) The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa. Ann Hematol 93:1785CrossRefPubMed Htun KT, McFadyen J, Tran HA (2014) The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa. Ann Hematol 93:1785CrossRefPubMed
29.
Zurück zum Zitat Dumkow LE, Voss JR, Peters M, Jennings DL (2012) Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm 69:1646CrossRefPubMed Dumkow LE, Voss JR, Peters M, Jennings DL (2012) Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm 69:1646CrossRefPubMed
30.
Zurück zum Zitat Perzborn E, Gruber A, Tinel H et al (2013) Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 110:162CrossRefPubMed Perzborn E, Gruber A, Tinel H et al (2013) Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 110:162CrossRefPubMed
31.
Zurück zum Zitat Pragst I, Zeitler SH, Doerr B et al (2012) Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 10:1841CrossRefPubMed Pragst I, Zeitler SH, Doerr B et al (2012) Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 10:1841CrossRefPubMed
32.
Zurück zum Zitat Pollack CV Jr, Reilly PA, Eikelboom J et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511CrossRefPubMed Pollack CV Jr, Reilly PA, Eikelboom J et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511CrossRefPubMed
33.
Zurück zum Zitat Pollack CV Jr, Reilly PA, van Ryn J et al (2017) Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med 377:431CrossRefPubMed Pollack CV Jr, Reilly PA, van Ryn J et al (2017) Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med 377:431CrossRefPubMed
34.
Zurück zum Zitat Schiele F, van Ryn J, Canada K et al (2013) A specific antidote for dabigatran: functional and structural characterization. Blood 121:3554CrossRefPubMed Schiele F, van Ryn J, Canada K et al (2013) A specific antidote for dabigatran: functional and structural characterization. Blood 121:3554CrossRefPubMed
35.
Zurück zum Zitat Getta B, Muller N, Motum P et al (2015) Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran. Br J Haematol 169:603CrossRefPubMed Getta B, Muller N, Motum P et al (2015) Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran. Br J Haematol 169:603CrossRefPubMed
36.
Zurück zum Zitat Chai-Adisaksopha C, Hillis C, Lim W et al (2015) Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. J Thromb Haemost 13:1790CrossRefPubMed Chai-Adisaksopha C, Hillis C, Lim W et al (2015) Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. J Thromb Haemost 13:1790CrossRefPubMed
37.
Zurück zum Zitat Stangier J, Rathgen K, Stähle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49:259CrossRefPubMed Stangier J, Rathgen K, Stähle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49:259CrossRefPubMed
38.
Zurück zum Zitat Zahir H, Brown KS, Vandell AG et al (2015) Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 131:82CrossRefPubMed Zahir H, Brown KS, Vandell AG et al (2015) Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 131:82CrossRefPubMed
39.
Zurück zum Zitat Majeed A, Ågren A, Holmström M et al (2017) Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 130:1706CrossRefPubMed Majeed A, Ågren A, Holmström M et al (2017) Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 130:1706CrossRefPubMed
40.
Zurück zum Zitat Camm AJ, Bounameaux H (2011) Edoxaban: a new oral direct factor xa inhibitor. Drugs 71:1503CrossRefPubMed Camm AJ, Bounameaux H (2011) Edoxaban: a new oral direct factor xa inhibitor. Drugs 71:1503CrossRefPubMed
41.
Zurück zum Zitat Parasrampuria DA, Marbury T, Matsushima N et al (2015) Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost 113:719CrossRefPubMed Parasrampuria DA, Marbury T, Matsushima N et al (2015) Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost 113:719CrossRefPubMed
42.
Zurück zum Zitat Lu G, DeGuzman FR, Hollenbach SJ et al (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19:446CrossRefPubMed Lu G, DeGuzman FR, Hollenbach SJ et al (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19:446CrossRefPubMed
43.
Zurück zum Zitat Siegal D, Lu G, Leeds JM et al (2017) Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. Blood Adv 1:1827CrossRefPubMedPubMedCentral Siegal D, Lu G, Leeds JM et al (2017) Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. Blood Adv 1:1827CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Connolly SJ, Milling TJ Jr, Eikelboom JW et al (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375:1131CrossRefPubMedPubMedCentral Connolly SJ, Milling TJ Jr, Eikelboom JW et al (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375:1131CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Laulicht B, Bakhru S, Jiang X et al (2013) Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. ISTH abstract 2013; :AS 47.1. Laulicht B, Bakhru S, Jiang X et al (2013) Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. ISTH abstract 2013; :AS 47.1.
46.
Zurück zum Zitat Ansell JE, Bakhru SH, Laulicht BE et al (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371:2141CrossRefPubMed Ansell JE, Bakhru SH, Laulicht BE et al (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371:2141CrossRefPubMed
47.
Zurück zum Zitat Thalji NK, Ivanciu L, Davidson R et al (2016) A rapid pro-hemostatic approach to overcome direct oral anticoagulants. Nat Med 22:924CrossRefPubMed Thalji NK, Ivanciu L, Davidson R et al (2016) A rapid pro-hemostatic approach to overcome direct oral anticoagulants. Nat Med 22:924CrossRefPubMed
Metadaten
Titel
Blutungen unter direkten oralen Antikoagulanzien
Auftreten und Therapie bei Intensivpatienten
verfasst von
Prof. Dr. H. M. Hoffmeister
H. Darius
M. Buerke
Publikationsdatum
04.05.2018

Weitere Artikel der Ausgabe 4/2018

Medizinische Klinik - Intensivmedizin und Notfallmedizin 4/2018 Zur Ausgabe

Mitteilungen der DGIIN

Mitteilungen der DGIIN

Passend zum Thema

ANZEIGE

Leitlinien-Update und neue Pocket-Leitlinie vorgestellt von Prof. Möllmann

Die neue Leitlinie zur Behandlung von Herzklappenerkrankungen der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS) ist ab jetzt als deutschsprachige Pocket-Leitlinien abrufbar. Die wichtigsten Neuerungen des Updates finden Sie hier von Prof. Dr. Helge Möllmann aus Dortmund für Sie zusammengefasst.

ANZEIGE

Expertenrat: Wer profitiert vom Vorhofohr-Verschluss

Der interventionelle Verschluss des linken Vorhofohrs ist eine in den Leitlinien empfohlene Alternative zur oralen Antikoagulation bei Menschen mit Vorhofflimmern. Bei welchen Patientinnen und Patienten Sie konkret an diese Alternative denken sollten – dazu gibt Kardiologe PD Dr. Zisis Dimitriadis alltagstaugliche Tipps.

ANZEIGE

Abbott Structural Heart

Content Hub

Wir helfen Menschen mit Strukturellen Herzerkrankungen ihre Lebensqualität zu verbessern. Entdecken Sie unser einzigartiges Produktportfolio für ihre Patienten.

Abbott Medical GmbH